The role of SH3BP2 in the pathophysiology of cherubism

Ernst J Reichenberger, Michael A Levine, Bjorn R Olsen, Maria E Papadaki, Steven A Lietman, Ernst J Reichenberger, Michael A Levine, Bjorn R Olsen, Maria E Papadaki, Steven A Lietman

Abstract

Cherubism is a rare bone dysplasia that is characterized by symmetrical bone resorption limited to the jaws. Bone lesions are filled with soft fibrous giant cell-rich tissue that can expand and cause severe facial deformity. The disorder typically begins in children at ages of 2-5 years and the bone resorption and facial swelling continues until puberty; in most cases the lesions regress spontaneously thereafter. Most patients with cherubism have germline mutations in the gene encoding SH3BP2, an adapter protein involved in adaptive and innate immune response signaling. A mouse model carrying a Pro416Arg mutation in SH3BP2 develops osteopenia and expansile lytic lesions in bone and some soft tissue organs. In this review we discuss the genetics of cherubism, the biological functions of SH3BP2 and the analysis of the mouse model. The data suggest that the underlying cause for cherubism is a systemic autoinflammatory response to physiologic challenges despite the localized appearance of bone resorption and fibrous expansion to the jaws in humans.

Figures

Figure 1
Figure 1
Gene map and protein structure of human SH3BP2 indicating mutations in the canonical cherubism mutation interval (amino acids 415-420) and mutations reported in the pleckstrin homology (PH) domain. The mutation in the SH2 domain has been found in tumor tissue of a patient with giant cell tumor. (Modified after Ueki et al., 2001)
Figure 2
Figure 2
Schematic diagram of SH3BP2 interactions and pathway for SH3BP2-induced increase in osteoclastogenesis.
Figure 3
Figure 3
The role of TNF-α, M-CSF and RANKL in the pathogenesis of cherubism. (Modified after Ueki et al., 2007)

References

    1. Jones WA. Familial multilocular cystic disease of the jaws. American Journal of Cancer. 1933;17:946–950.
    1. Jones WA, Gerrie J, Pritchard J. Cherubism--familial fibrous dysplasia of the jaws. J Bone Joint Surg Br. 1950;32-B:334–347.
    1. Papadaki ME, Lietman SA, Levine MA, Olsen BR, Kaban LB, Reichenberger EJ. Cherubism: Best Clinical Practice Orphanet. Orphanet Journal of Rare Diseases. 2012;7(Suppl 1):S6. doi: 10.1186/1750-1172-7-S1-S6.
    1. Anderson DE, McClendon JL. Cherubism - hereditary fibrous dysplasia of the jaws. I. Genetic considerations. Oral Surgery Oral Medicine Oral Pathology. 1962;15:5–16.
    1. Von Wowern N. Cherubism: a 36-year long-term follow-up of 2 generations in different families and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:765–772. doi: 10.1067/moe.2000.108438.
    1. Tiziani V, Reichenberger E, Buzzo CL, Niazi S, Fukai N, Stiller M, Peters H, Salzano FM, Raposo do Amaral CM, Olsen BR. The gene for cherubism maps to chromosome 4p16. Am J Hum Genet. 1999;65:158–166. doi: 10.1086/302456.
    1. Mangion J, Rahman N, Edkins S, Barfoot R, Nguyen T, Sigurdsson A, Townend JV, Fitzpatrick DR, Flanagan AM, Stratton MR. The gene for cherubism maps to chromosome 4p16.3. American Journal of Human Genetics. 1999;65:151–157. doi: 10.1086/302454.
    1. Hadano S, Ishida Y, Ikeda JE. The primary structure and genomic organization of five novel transcripts located close to the Huntington's disease gene on human chromosome 4p16.3. DNA Res. 1998;5:177–186. doi: 10.1093/dnares/5.3.177.
    1. Zollino M, DS C, Zampino G, Mastroiacovo P, Wright TJ, Sorge G, Selicorni A, Tenconi R, Zappala A, Battaglia A, Di Rocco M, Palka G, Pallotta R, Altherr MR, Neri G. Genotype-phenotype correlations and clinical diagnostic criteria in wolf-hirschhorn syndrome. Am J Med Genet. 2000;94:254–261. doi: 10.1002/1096-8628(20000918)94:3<254::AID-AJMG13>;2-7.
    1. Bell SM, Shaw M, Jou YS, Myers RM, Knowles MA. Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer. Genomics. 1997;44:163–170. doi: 10.1006/geno.1997.4849.
    1. Ueki Y, Tiziani V, Santanna C. et al.Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet. 2001;28:125–126. doi: 10.1038/88832.
    1. Ren R, Mayer BJ, Cicchetti P, Baltimore D. Identification of a ten-amino acid proline-rich SH3 binding site. Science. 1993;259:1157–1161. doi: 10.1126/science.8438166.
    1. Deckert M, Rottapel R. The adapter 3BP2: how it plugs into leukocyte signaling. Adv Exp Med Biol. 2006;584:107–114. doi: 10.1007/0-387-34132-3_8.
    1. Le Bras S, Foucault I, Foussat A, Brignone C, Acuto O, Deckert M. Recruitment of the actin-binding protein HIP-55 to the immunological synapse regulates T cell receptor signaling and endocytosis. J Biol Chem. 2004;279:15550–15560. doi: 10.1074/jbc.M312659200.
    1. Le Bras S, Moon C, Foucault I, Breittmayer JP, Deckert M. Abl-SH3 binding protein 2, 3BP2, interacts with CIN85 and HIP-55. FEBS Lett. 2007;581:967–974. doi: 10.1016/j.febslet.2007.01.084.
    1. Lietman SA, Kalinchinko N, Deng X, Kohanski R, Levine MA. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation. Hum Mutat. 2006;27:717–718.
    1. de Lange J, van Maarle MC, van den Akker HP, Redeker EJ. A new mutation in the SH3BP2 gene showing reduced penetrance in a family affected with cherubism. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:378–381. doi: 10.1016/j.tripleo.2006.05.012.
    1. Lo B, Faiyaz-Ul-Haque M, Kennedy S, Aviv R, Tsui LC, Teebi AS. Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism. Am J Med Genet A. 2003;121A:37–40. doi: 10.1002/ajmg.a.20226.
    1. Li CY, Yu SF. A novel mutation in the SH3BP2 gene causes cherubism: case report. BMC Med Genet. 2006;7:84. doi: 10.1186/1471-2350-7-84.
    1. Carvalho VM, Perdigao PF, Amaral FR, de Souza PE, De Marco L, Gomez RS. Novel mutations in the SH3BP2 gene associated with sporadic central giant cell lesions and cherubism. Oral Dis. 2009;15:106–110. doi: 10.1111/j.1601-0825.2008.01499.x.
    1. Carvalho VM, Perdigao PF, Pimenta FJ, de Souza PE, Gomez RS, De Marco L. A novel mutation of the SH3BP2 gene in an aggressive case of cherubism. Oral Oncol. 2008;44:153–155. doi: 10.1016/j.oraloncology.2007.01.012.
    1. Silva EC, de Souza PE, Barreto DC, Dias RP, Gomez RS. An extreme case of cherubism. Br J Oral Maxillofac Surg. 2002;40:45–48. doi: 10.1054/bjom.2001.0654.
    1. Cohen MM Jr., Gorlin RJ. Noonan-like/multiple giant cell lesion syndrome. Am J Med Genet. 1991;40:159–166. doi: 10.1002/ajmg.1320400208.
    1. Tartaglia M, Kalidas K, Shaw A. et al.PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70:1555–1563. doi: 10.1086/340847.
    1. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1:2–26. doi: 10.1159/000276766.
    1. Bufalino A, Carrera M, Carlos R, Coletta RD. Giant cell lesions in noonan syndrome: case report and review of the literature. Head Neck Pathol. 2010;4:174–177. doi: 10.1007/s12105-010-0178-2.
    1. Jafarov T, Ferimazova N, Reichenberger E. Noonan-like syndrome mutations in PTPN11 in patients diagnosed with cherubism. Clin Genet. 2005;68:190–191.
    1. Lee JS, Tartaglia M, Gelb BD, Fridrich K, Sachs S, Stratakis CA, Muenke M, Robey PG, Collins MT, Slavotinek A. Phenotypic and genotypic characterisation of Noonan-like/multiple giant cell lesion syndrome. J Med Genet. 2005;42:e11. doi: 10.1136/jmg.2004.024091.
    1. Sarkozy A, Obregon MG, Conti E, Esposito G, Mingarelli R, Pizzuti A, Dallapiccola B. A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome. Eur J Hum Genet. 2004;12:1069–1072. doi: 10.1038/sj.ejhg.5201290.
    1. Beneteau C, Cave H, Moncla A, Dorison N, Munnich A, Verloes A, Leheup B. SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. Eur J Hum Genet. 2009;17:1216–1221. doi: 10.1038/ejhg.2009.44.
    1. Hanna N, Parfait B, Talaat IM, Vidaud M, Elsedfy HH. SOS1: a new player in the Noonan-like/multiple giant cell lesion syndrome. Clin Genet. 2009;75:568–571. doi: 10.1111/j.1399-0004.2009.01149.x.
    1. van Capelle CI, Hogeman PH, van der Sijs-Bos CJ, Heggelman BG, Idowu B, Slootweg PJ, Wittkampf AR, Flanagan AM. Neurofibromatosis presenting with a cherubism phenotype. Eur J Pediatr. 2007;166:905–909. doi: 10.1007/s00431-006-0334-6.
    1. Ruggieri M, Pavone V, Polizzi A, Albanese S, Magro G, Merino M, Duray PH. Unusual form of recurrent giant cell granuloma of the mandible and lower extremities in a patient with neurofibromatosis type 1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;87:67–72. doi: 10.1016/S1079-2104(99)70297-0.
    1. De Luca A, Bottillo I, Sarkozy A. et al.NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet. 2005;77:1092–1101. doi: 10.1086/498454.
    1. Bertola DR, Pereira AC, Passetti F, de Oliveira PS, Messiaen L, Gelb BD, Kim CA, Krieger JE. Neurofibromatosis-Noonan syndrome: molecular evidence of the concurrence of both disorders in a patient. Am J Med Genet A. 2005;136:242–245.
    1. Stamm S, Riethoven JJ, Le Texier V, Gopalakrishnan C, Kumanduri V, Tang Y, Barbosa-Morais NL, Thanaraj TA. ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res. 2006;34:D46–55. doi: 10.1093/nar/gkj031.
    1. Proulx-Bonneau S, Guezguez A, Annabi B. A concerted HIF-1α/MT1-MMP signalling axis regulates the expression of the 3BP2 adaptor protein in hypoxic mesenchymal stromal cells. PLoS One. 2011;6:e21511. doi: 10.1371/journal.pone.0021511.
    1. de la Fuente MA, Kumar L, Lu B, Geha RS. 3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation. Mol Cell Biol. 2006;26:5214–5225. doi: 10.1128/MCB.00087-06.
    1. Foucault I, Le Bras S, Charvet C, Moon C, Altman A, Deckert M. The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood. 2005;105:1106–1113.
    1. Foucault I, Liu YC, Bernard A, Deckert M. The chaperone protein 14-3-3 interacts with 3BP2/SH3BP2 and regulates its adapter function. J Biol Chem. 2003;278:7146–7153. doi: 10.1074/jbc.M209509200.
    1. Jevremovic D, Billadeau DD, Schoon RA, Dick CJ, Leibson PJ. Regulation of NK cell-mediated cytotoxicity by the adaptor protein 3BP2. J Immunol. 2001;166:7219–7228.
    1. Maeno K, Sada K, Kyo S, Miah SM, Kawauchi-Kamata K, Qu X, Shi Y, Yamamura H. Adaptor protein 3BP2 is a potential ligand of Src homology 2 and 3 domains of Lyn protein-tyrosine kinase. J Biol Chem. 2003;278:24912–24920. doi: 10.1074/jbc.M301201200.
    1. Sada K, Miah SM, Maeno K, Kyo S, Qu X, Yamamura H. Regulation of FcepsilonRI-mediated degranulation by an adaptor protein 3BP2 in rat basophilic leukemia RBL-2H3 cells. Blood. 2002;100:2138–2144. doi: 10.1182/blood-2001-12-0340.
    1. Deckert M, Tartare-Deckert S, Hernandez J, Rottapel R, Altman A. Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. Immunity. 1998;9:595–605. doi: 10.1016/S1074-7613(00)80657-3.
    1. Faccio R, Teitelbaum SL, Fujikawa K, Chappel J, Zallone A, Tybulewicz VL, Ross FP, Swat W. Vav3 regulates osteoclast function and bone mass. Nat Med. 2005;11:284–290. doi: 10.1038/nm1194.
    1. Qu X, Kawauchi-Kamata K, Miah SM, Hatani T, Yamamura H, Sada K. Tyrosine phosphorylation of adaptor protein 3BP2 induces T cell receptor-mediated activation of transcription factor. Biochemistry. 2005;44:3891–3898. doi: 10.1021/bi048353o.
    1. Zou W, Teitelbaum SL. Integrins, growth factors, and the osteoclast cytoskeleton. Ann N Y Acad Sci. 2010;1192:27–31. doi: 10.1111/j.1749-6632.2009.05245.x.
    1. Chiusaroli R, Sanjay A, Henriksen K, Engsig MT, Horne WC, Gu H, Baron R. Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones. Dev Biol. 2003;261:537–547. doi: 10.1016/S0012-1606(03)00299-9.
    1. Peruzzi G, Molfetta R, Gasparrini F, Vian L, Morrone S, Piccoli M, Frati L, Santoni A, Paolini R. The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway. J Immunol. 2007;179:2089–2096.
    1. Yu Z, Maoui M, Zhao ZJ, Li Y, Shen SH. SHP-1 dephosphorylates 3BP2 and potentially downregulates 3BP2-mediated T cell antigen receptor signaling. FEBS J. 2006;273:2195–2205. doi: 10.1111/j.1742-4658.2006.05233.x.
    1. Saborit-Villarroya I, Del Valle JM, Romero X, Esplugues E, Lauzurica P, Engel P, Martin M. The adaptor protein 3BP2 binds human CD244 and links this receptor to Vav signaling, ERK activation, and NK cell killing. J Immunol. 2005;175:4226–4235.
    1. Ueki Y, Lin CY, Senoo M. et al.Increased Myeloid Cell Responses to M-CSF and RANKL Cause Bone Loss and Inflammation in SH3BP2 "Cherubism" Mice. Cell. 2007;128:71–83. doi: 10.1016/j.cell.2006.10.047.
    1. GuezGuez A, Prod'homme V, Mouska X, Baudot A, Blin-Wakkach C, Rottapel R, Deckert M. 3BP2 Adapter protein is required for receptor activator of NFkappaB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells. J Biol Chem. 2010;285:20952–20963. doi: 10.1074/jbc.M109.091124.
    1. Bergemann AD, Cole F, Hirschhorn K. The etiology of Wolf-Hirschhorn syndrome. Trends Genet. 2005;21:188–195. doi: 10.1016/j.tig.2005.01.008.
    1. Battaglia A, Carey JC. Health supervision and anticipatory guidance of individuals with Wolf-Hirschhorn syndrome. Am J Med Genet. 1999;89:111–115. doi: 10.1002/(SICI)1096-8628(19990625)89:2<111::AID-AJMG9>;2-G.
    1. Battaglia A, Carey JC, Cederholm P, Viskochil DH, Brothman AR, Galasso C. Natural history of Wolf-Hirschhorn syndrome: experience with 15 cases. Pediatrics. 1999;103:830–836. doi: 10.1542/peds.103.4.830.
    1. Takayanagi H, Kim S, Koga T. et al.Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3:889–901. doi: 10.1016/S1534-5807(02)00369-6.
    1. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T. Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem. 2002;277:41147–41156. doi: 10.1074/jbc.M205063200.
    1. Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem. 2004;279:13984–13992. doi: 10.1074/jbc.M213067200.
    1. Bellows CG, Ishida H, Aubin JE, Heersche JN. Parathyroid hormone reversibly suppresses the differentiation of osteoprogenitor cells into functional osteoblasts. Endocrinology. 1990;127:3111–3116. doi: 10.1210/endo-127-6-3111.
    1. Komarova SV, Pereverzev A, Shum JW, Sims SM, Dixon SJ. Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calcineurin/NFAT pathway in osteoclasts. Proc Natl Acad Sci U S A. 2005;102:2643–2648. doi: 10.1073/pnas.0406874102.
    1. Uhlen P, Burch PM, Zito CI, Estrada M, Ehrlich BE, Bennett AM. Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. Proc Natl Acad Sci U S A. 2006;103:2160–2165. doi: 10.1073/pnas.0510876103.
    1. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med. 2005;83:170–179. doi: 10.1007/s00109-004-0612-6.
    1. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol. 2003;4:557–564. doi: 10.1038/ni929.
    1. Koga T, Inui M, Inoue K. et al.Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004;428:758–763. doi: 10.1038/nature02444.
    1. Lietman SA, Yin L, Levine MA. SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun. 2008;371:644–648. doi: 10.1016/j.bbrc.2008.04.080.
    1. Lietman SA, Yin L, Levine MA. SH3BP2 mutations potentiate osteoclastogenesis via PLCgamma. J Orthop Res. 2010;28:1425–1430. doi: 10.1002/jor.21164.
    1. Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R. PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest. 2006;116:2869–2879. doi: 10.1172/JCI28775.
    1. Patterson RL, van Rossum DB, Ford DL, Hurt KJ, Bae SS, Suh PG, Kurosaki T, Snyder SH, Gill DL. Phospholipase C-gamma is required for agonist-induced Ca2+ entry. Cell. 2002;111:529–541. doi: 10.1016/S0092-8674(02)01045-0.
    1. Wilde JI, Watson SP. Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other? Cell Signal. 2001;13:691–701. doi: 10.1016/S0898-6568(01)00191-7.
    1. Rebecchi MJ, Pentyala SN. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol Rev. 2000;80:1291–1335.
    1. Katan M. Families of phosphoinositide-specific phospholipase C: structure and function. Biochim Biophys Acta. 1998;1436:5–17.
    1. Watanabe D, Hashimoto S, Ishiai M, Matsushita M, Baba Y, Kishimoto T, Kurosaki T, Tsukada S. Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling. J Biol Chem. 2001;276:38595–38601. doi: 10.1074/jbc.M103675200.
    1. Humphries LA, Dangelmaier C, Sommer K, Kipp K, Kato RM, Griffith N, Bakman I, Turk CW, Daniel JL, Rawlings DJ. Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem. 2004;279:37651–37661. doi: 10.1074/jbc.M311985200.
    1. Kim YJ, Sekiya F, Poulin B, Bae YS, Rhee SG. Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol. 2004;24:9986–9999. doi: 10.1128/MCB.24.22.9986-9999.2004.
    1. Hur EM, Park YS, Lee BD, Jang IH, Kim HS, Kim TD, Suh PG, Ryu SH, Kim KT. Sensitization of epidermal growth factor-induced signaling by bradykinin is mediated by c-Src. Implications for a role of lipid microdomains. J Biol Chem. 2004;279:5852–5860.
    1. Jongstra-Bilen J, Puig Cano A, Hasija M, Xiao H, Smith CI, Cybulsky MI. Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol. 2008;181:288–298.
    1. Mukherjee PM, Wang CJ, Chen IP, Jafarov T, Olsen BR, Ueki Y, Reichenberger EJ. Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function. Am J Orthod Dentofacial Orthop. 2010;138:140. doi: 10.1016/j.ajodo.2010.04.004. e141-140 e111; discussion 140-141.
    1. Chipman SD, Sweet HO, McBride DJ Jr., Davisson MT, Marks SC Jr., Shuldiner AR, Wenstrup RJ, Rowe DW, Shapiro JR. Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: a model of human osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1993;90:1701–1705. doi: 10.1073/pnas.90.5.1701.
    1. Chen IP, Wang CJ, Strecker S, Koczon-Jaremko B, Boskey A, Reichenberger EJ. Introduction of a Phe377del mutation in ANK creates a mouse model for craniometaphyseal dysplasia. J Bone Miner Res. 2009;24:1206–1215. doi: 10.1359/jbmr.090218.
    1. Adler CP, Harle F. 23. Zur Differentialdiagnose osteo-fibroser Kieferekrankungen. Verhandlungen der Deutschen Gesellschaft fur Pathologie. 1974;58:308–314.
    1. Liao BY, Zhang J. Null mutations in human and mouse orthologs frequently result in different phenotypes. Proc Natl Acad Sci U S A. 2008;105:6987–6992. doi: 10.1073/pnas.0800387105.
    1. Wang CJ, Chen IP, Koczon-Jaremko B, Boskey AL, Ueki Y, Kuhn L, Reichenberger EJ. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties. Bone. 2010;46:1306–1315. doi: 10.1016/j.bone.2010.01.380.
    1. Kalajzic I, Kalajzic Z, Kaliterna M, Gronowicz G, Clark SH, Lichtler AC, Rowe D. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J Bone Miner Res. 2002;17:15–25. doi: 10.1359/jbmr.2002.17.1.15.
    1. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR, Glimcher LH. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest. 2008;118:3775–3789. doi: 10.1172/JCI35711.
    1. Kaminuma O, Kitamura F, Kitamura N, Hiroi T, Miyoshi H, Miyawaki A, Miyatake S. Differential contribution of NFATc2 and NFATc1 to TNF-alpha gene expression in T cells. J Immunol. 2008;180:319–326.
    1. Chen G, Dimitriou ID, La Rose J, Ilangumaran S, Yeh WC, Doody G, Turner M, Gommerman J, Rottapel R. The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response. Mol Cell Biol. 2007;27:3109–3122. doi: 10.1128/MCB.01014-06.
    1. Ferguson PJ, El-Shanti HI. Autoinflammatory bone disorders. Curr Opin Rheumatol. 2007;19:492–498. doi: 10.1097/BOR.0b013e32825f5492.
    1. Chitkara P, Stojanov S, Kastner DL. The hereditary autoinflammatory syndromes. Pediatr Infect Dis J. 2007;26:353–354. doi: 10.1097/01.inf.0000258777.86510.da.
    1. McGonagle D, Aziz A, Dickie LJ, McDermott MF. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res. 2009;65:38R–45R. doi: 10.1203/PDR.0b013e31819dbd0a.
    1. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297.
    1. Nicolae C, Olsen BR. Unexpected matrix diseases and novel therapeutic strategies. Cell Tissue Res. 2010;339:155–165. doi: 10.1007/s00441-009-0874-y.
    1. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–160. doi: 10.1002/path.2287.
    1. Ueki Y, Mukai T, Yoshitaka T. Mechanism of inflammation in cherubism. In J Bone Miner Res. 2010;25(Suppl 1) Available at [ ] Accessed [12-24-2010]
    1. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest. 1997;100:1557–1565. doi: 10.1172/JCI119679.
    1. Liu J, Wang S, Zhang P, Said-Al-Naief N, Michalek SM, Feng X. Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis. J Biol Chem. 2009;284:12512–12523. doi: 10.1074/jbc.M809789200.
    1. Tomomatsu N, Aoki K, Alles N, Soysa NS, Hussain A, Nakachi H, Kita S, Shimokawa H, Ohya K, Amagasa T. LPS-induced inhibition of osteogenesis is TNF-alpha dependent in a murine tooth extraction model. J Bone Miner Res. 2009;24:1770–1781. doi: 10.1359/jbmr.090410.
    1. Kadono H, Kido J, Kataoka M, Yamauchi N, Nagata T. Inhibition of osteoblastic cell differentiation by lipopolysaccharide extract from Porphyromonas gingivalis. Infect Immun. 1999;67:2841–2846.
    1. Bandow K, Maeda A, Kakimoto K, Kusuyama J, Shamoto M, Ohnishi T, Matsuguchi T. Molecular mechanisms of the inhibitory effect of lipopolysaccharide (LPS) on osteoblast differentiation. Biochem Biophys Res Commun. 2010;402:755–761. doi: 10.1016/j.bbrc.2010.10.103.
    1. Akira S. Toll-like receptor signaling. J Biol Chem. 2003;278:38105–38108. doi: 10.1074/jbc.R300028200.
    1. Sato N, Takahashi N, Suda K. et al.MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide, and IL-1alpha. J Exp Med. 2004;200:601–611. doi: 10.1084/jem.20040689.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel